
ROCHE HOLDING LTD S/ADR by Roche rose 35.2% from $44.58 to $60.25, ahead of the S&P 500's +10.0%. Its worst day was Mar 5 (−6.3%), and its low came Nov 17 at $44.58.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
ROCHE HOLDING LTD S/ADR by Roche shares rose 9.6%, while the S&P 500 fell 0.8%.
+9.6%, the year's best day, on 11M shares, the year's heaviest volume · S&P 500 −0.8%
Roche reported 2025 sales of CHF 61.5 billion, driven by strong drug demand, rising profits, higher EPS, and a proposed dividend increase, with steady growth expected in 2026.
Story events cover the past 12 months · Times ET
+4.8% · S&P 500 −0.2%
– Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerability –– At the maximally effective dose, there were no cases
−6.3%, the year's worst day · S&P 500 −0.6%
ROCHE HOLDING LTD S/ADR by Roche shares rose 5.2%, while the S&P 500 rose 0.4%.
+5.2% · S&P 500 +0.4%
ROCHE HOLDING LTD S/ADR by Roche shares rose 5.4%, while the S&P 500 fell 0.1%.
+5.4% · S&P 500 −0.1%
ROCHE HOLDING LTD S/ADR by Roche shares rose 4.8%, while the S&P 500 rose 0.2%.
+4.8% · S&P 500 +0.2%
ROCHE HOLDING LTD S/ADR by Roche closed at its highest level of the year, 37.6% above where the year started.
+3.3% · S&P 500 +2.4%
Where it ended: a close of $60.25 on Nov 17, 2026.
Nothing in the past 12 months.
All RHHBY earningsNothing in the past 12 months.
All RHHBY analyst actionsNothing in the past 12 months.
All RHHBY dividend history